A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study
to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in
adult subjects with active systemic lupus erythematosus.
Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to
receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.